Europe Biodefense Market to Grow at a CAGR of 8.8% to reach US$ 1,286.58 Million from 2020 to 2027

Europe Biodefense Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Anthrax, Small pox, Botulism, Radiation/Nuclear, Others), and Geography

Publication Month: Apr 2020 | Report Code: TIPRE00010410 | No. of Pages: 105 | Category: Biotechnology | Status: Published
Covid

The Europe Biodefense market is expected to reach US$ 1,286.58 Mn in 2027 from US$ 2,516.91 Mn in 2019. The market is estimated to grow with a CAGR of 8.8% from 2019-2027.

 

The growth of the Biodefense market is driven by factors such as the favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM in the Europe region. However, fluctuations in funding due to changing EU is likely to restrain the market growth to a certain extent.

 

Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.

 

Disease outbreaks are usually caused by an infection, transmitted through person-to-person contact, animal-to-person contact, or from the environment or other media. Emerging infectious diseases are infections that have recently appeared within a population and are rapidly increasing or threaten to grow shortly. The World Health Organization warned in its 2007 report that infectious diseases are emerging at a rate that has not been seen before. Since the 1970s, about 40 infectious diseases have been discovered, including SARS, MERS, Ebola, chikungunya, avian flu, swine flu, zika, and most recently, coronavirus. In May through June 2011, a novel strain of Escherichia coli O104:H4 bacteria caused a significant outbreak of foodborne disease focused in northern Germany. In total, there were 3,950 people affected and 53 died, 51 of whom were from Germany. 800 people suffered from hemolytic uremic syndrome (HUS), which would lead to kidney failure. The growing prevalence of Ebola and Zika virus infections is also likely to contribute to the Biodefense market development. Due to coronavirus outbreak, As of 15 April, there have been 98,476 confirmed cases of COVID-19 in the UK, and 12,868 people with confirmed infection have died. Further, on March 18, 2020 Emergent BioSolutions signed development and manufacturing agreement with Vaxart for their experimental oral vaccine candidate for Coronavirus Disease.

 

The release of pathogenic agents such as anthrax or smallpox, biological toxins, chemical weapons such as nerve gas, or radioactive substances caused public threats in the past. In order to prevent such outbreaks, the government has planned various strategies. The growing prevalence of infectious diseases, such as coronavirus, Ebola and zika virus, is likely to boost the investments in the field of biodefense, thereby driving the Biodefense market growth.

 

Biological weapons (BWs) deliver toxins and microorganisms, such as viruses and bacteria, so as to intentionally inflict disease among people, animals, and agriculture. Biological attacks can result in destruction of crops, temporarily discomforting a small community, killing large numbers of people, or other outcomes. Biological weapons have a long history of use. In 1346, the invading Tartar army catapulted the bodies of plague victims into the Crimean Peninsula city of Kaffa and infected its citizens. In 1763, British troops under General Jeffrey Amherst gave the Delaware Indians blankets used by people with smallpox, possibly infecting the susceptible native population. Although recent advances in biotechnology have made it easier to develop dangerous viruses, bacteria, and toxins with fewer resources. This has increased concerns that individuals and groups could resort to bioterrorism to attack a population.

 

Moreover, due to factors such as increasing border threats, rising national security concerns, and changing dynamics of warfare, countries such as Russia, UK in Western Europe are inclined towards enhancing their missile weapon store. They are also modernizing their old missiles with the new propulsion system and warheads. Hence, as the threat for biological weapon and nuclear armed ICBM is increasing, governments of various countries are actively funding for biodefense, thereby, positively propelling the European market.

 

Rest of Europe Biodefense market Revenue and Forecasts to 2027 (US$ Bn)

Rest of Europe Biodefense market Revenue and Forecasts to 2027 (US$ Bn)

Get more information on this report :

EUROPE BIODEFENSE MARKET – MARKET SEGMENTATION

Europe Biodefense Market – By Product

  • Anthrax
  • Small pox
  • Botulism
  • Radiation/Nuclear
  • Others

Europe Biodefense Market – By Country

  • United Kingdom
  • Germany
  • France
  • Spain
  • Italy

Companies Mentioned

  • Bavarian Nordic
  • Alnylam Pharmaceuticals, Inc.
  • SIGA Technologies
  • Emergent BioSolutions Inc.
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Soligenix
  • Altimmune
  • Pluristem Therapeutics

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        Europe Biodefense market – By Product

1.3.2        Europe Biodefense market – By Country

2.           Europe Biodefense Market – Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Europe Biodefense market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        Biodefense market - Europe PEST Analysis

4.3         Expert Opinion

5.           Europe Biodefense Market - Key Market Dynamics

5.1         Key Market Drivers

5.1.1        Presence of Favourable Government Initiatives

5.1.2        Increase in the Number of Naturally Occurring Outbreaks

5.1.3        Increasing Threat of Biological Weapons and Nuclear Armed ICBM

5.2         Key Market Restraints

5.2.1        Fluctuations in funding due to the changing EU & government policies

5.3         Key Market Opportunities

5.3.1        Increased Adoption of Technologies

5.4         Future Trends

5.4.1        Predictive Analytics to Reshape Biodefense Market

5.5         Impact Analysis

6.           Biodefense Market – Europe Analysis

6.1         Europe Biodefense Market Revenue Forecasts and Analysis

7.           Europe Biodefense market Analysis And Forecasts To 2027 – By Product

7.1         Overview

7.2         Europe Biodefense market, By Product 2019 & 2027 (%)

7.2.1        Europe Biodefense market Revenue and Forecasts to 2027, By Product (US$ Mn)

7.3         Anthrax

7.3.1        Overview

7.3.2        Europe Anthrax Market Revenue and Forecast to 2027 (US$ Mn)

7.4         Small pox

7.4.1        Overview

7.4.2        Europe Small Pox Market Revenue and Forecasts to 2027 (US$ Mn)

7.5         Botulism

7.5.1        Overview

7.5.2        Europe Botulism Market Revenue and Forecasts to 2027 (US$ Mn)

7.6         Radiation/Nuclear

7.6.1        Overview

7.6.2        Europe Radiation/Nuclear Market Revenue and Forecasts to 2027 (US$ Mn)

7.7         Others

7.7.1        Overview

7.7.2        Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)

8.           Biodefense market Revenue and Forecasts To 2027 – Geographical Analysis

8.1         Europe Biodefense market Revenue and Forecasts To 2027

8.1.1        Overview

8.1.2        Europe: Biodefense Market - Revenue and Forecast to 2027 (USD Million)

8.1.3        Europe: Biodefense Market, by Product, 2018–2027 (USD Million)

8.1.4        Europe: Biodefense Market, by Country, 2018 & 2027 (%)

8.1.5        Germany: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.5.1          Germany: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.5.2          Germany: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.6        UK: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.6.1          UK: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.6.2          UK: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.7        France: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.7.1          France: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.7.2          France: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.8        Spain: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.8.1          Spain: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.8.2          Spain: Biodefense Market, by Product Type, 2018–2027 (USD Million)

8.1.9        Italy: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.9.1          Italy: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

8.1.9.2          Italy: Biodefense Market, by Product Type, 2018–2027 (USD Million)

9.           Impact 0f Covid-19 Pandemic On Europe Biodefense Market

9.1         Europe: Impact assessment of COVID-19 Pandemic

10.        Europe Biodefense market Industry Landscape

10.1      Overview

10.2      Growth Strategies in The Biodefense Market, 2016-2020

10.3      Inorganic Growth Strategies

10.3.1     Overview

10.4      Organic Growth Strategies

10.4.1     Overview

11.        Company Profiles

11.1      Bavarian Nordic

11.1.1     Key Facts

11.1.2     Business Description

11.1.3     Products and Services

11.1.4     Financial Overview

11.1.5     SWOT Analysis

11.1.6     Key Developments

11.2      Alnylam Pharmaceuticals, Inc.

11.2.1     Key Facts

11.2.2     Business Description

11.2.3     Products and Services

11.2.4     Financial Overview

11.2.5     SWOT Analysis

11.2.6     Key Developments

11.3      SIGA Technologies

11.3.1     Key Facts

11.3.2     Business Description

11.3.3     Products and Services

11.3.4     Financial Overview

11.3.5     SWOT Analysis

11.3.6     Key Developments

11.4      Emergent BioSolutions Inc.

11.4.1     Key Facts

11.4.2     Business Description

11.4.3     Products and Services

11.4.4     Financial Overview

11.4.5     SWOT Analysis

11.4.6     Key Developments

11.5      Cleveland Bio Labs

11.5.1     Key Facts

11.5.2     Business Description

11.5.3     Products and Services

11.5.4     Financial Overview

11.5.5     SWOT Analysis

11.5.6     Key Developments

12.        Appendix

12.1      About The Insight Partners

12.2      Glossary of Terms

 


LIST OF TABLES

Table 1.             Europe Biodefense market Revenue and Forecasts To 2027, By Product (US$ Mn)

Table 2.             Europe Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 3.             Germany Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 4.             UK Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 5.             France Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 6.             Spain Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 7.             Itlay Biodefense Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 8.             Recent Inorganic Growth Strategies In The Biodefense Market

Table 9.             Recent Organic Growth Strategies In The Biodefense Market

Table 10.          Glossary of Terms, Biodefense Market

 


LIST OF FIGURES

Figure 1.           Biodefense market Segmentation

Figure 2.           Europe Biodefense market Overview

Figure 3.           Anthrax Segment Held Largest Share of Product Segment in Biodefense Market

Figure 4.           Germany is Expected to Show Remarkable Growth During the Forecast Period

Figure 5.           Europe Biodefense market- Leading Country Markets (US$ Mn)

Figure 6.           Europe Biodefense market, Industry Landscape

Figure 7.           Biodefense market - Europe PEST Analysis

Figure 8.           Biodefense market Impact Analysis of Drivers and Restraints

Figure 9.           Europe Biodefense market – Revenue Forecasts and Analysis – 2019- 2027

Figure 10.        Europe Biodefense market, By Product 2019 & 2027 (%)

Figure 11.        Europe Anthrax Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.        Europe Small Pox Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 13.        Europe Botulism Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.        Europe Radiation/Nuclear Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15.        Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16.        Europe: Biodefense Market, by Key Country – Revenue (2019) (USD Million)

Figure 17.        Europe Biodefense Market Revenue and Forecast to 2027 (USD Million)

Figure 18.        Europe: Biodefense Market, by Country, 2018 & 2027 (%)

Figure 19.        Germany: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 20.        UK: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 21.        France: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 22.        Spain: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 23.        Italy: Biodefense Market – Revenue and Forecast to 2027 (USD Million)

Figure 24.        Impact Of Covid-19 Pandemic In European Country Markets

Figure 25.        Growth Strategies in the Biodefense Market, 2016-2020

 

The List of Companies - Europe Biodefense Market

  1. Bavarian Nordic
  2. Alnylam Pharmaceuticals, Inc.
  3. SIGA Technologies
  4. Emergent BioSolutions Inc.
  5. Cleveland Bio Labs
  6. Dynavax Technologies
  7. Elusys Therapeutics, Inc.
  8. Soligenix
  9. Altimmune
  10. Pluristem Therapeutics

 

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe biodefense market.

 

  • Highlights key business priorities in order to assist companies to realign their business strategies.

 

  • The key findings and recommendations highlight crucial progressive industry trends in the Europe biodefense market, thereby allowing players across the value chain to develop effective long-term strategies.

 

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

 

  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.

 

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

 

TIPRE00010410
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing